To debate the utility and appropriateness of real-world evidence against clinical trials for treating patients with hematologic malignancies, Chadi welcomes back Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, and Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), as well as invites first-time guest Liz Brem (@DrLizBrem), MD, assistant clinical professor of hematology, UC Irvine. Can RCT designers ever escape inherent bias? Will we ever enroll a more diverse, higher volume patient population in clinical trials? Who has the right to criticize a clinical trial design? The group uses a phase I study published in Lancet Hematology to frame their arguments in this riveting, hotly contested discussion.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA